CD8A and neoplasm: At first, only CD4+/CD8+ T cells engineered with AsNRs were i.v. injected; however, we found that, in the presence of engineered cells alone, the tumor cells were difficult to kill, and the treatment had unsatisfactory results (Fig. 7e and Supplementary Fig. 10d).